Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 6.55M shares outstanding
USExicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology.
Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain.
The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Dr. Mirkin
Dr. Walt
Jungsoo Kim
Chief Executive Officer, President & Director
Devki Sukhtankar
Head of Preclinical Research & Translational Medicine
Employees
7
Country
US
Sector
Healthcare
Website
exicuretx.com
Loading congressional disclosures…
based on 6.55M shares outstanding
US30d Avg
30.79K
60d Avg
39.67K
90d Avg
404.08K
